Intellia Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NTLA and other ETFs, options, and stocks.

About NTLA

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.

CEO

John M. Leonard

CEOJohn M. Leonard

Employees

403

Employees403

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2014

Founded2014

Employees

403

Employees403

NTLA Key Statistics

Market cap

836.95M

Market cap836.95M

Price-Earnings ratio

-1.54

Price-Earnings ratio-1.54

Dividend yield

—

Dividend yield—

Average volume

3.71M

Average volume3.71M

High today

$8.13

High today$8.13

Low today

$7.62

Low today$7.62

Open price

$7.85

Open price$7.85

Volume

1.91M

Volume1.91M

52 Week high

$28.18

52 Week high$28.18

52 Week low

$5.90

52 Week low$5.90

NTLA News

TipRanks 4d

Intellia Therapeutics price target lowered to $45 from $55 at Guggenheim

Guggenheim lowered the firm’s price target on Intellia Therapeutics (NTLA) to $45 from $55 and keeps a Buy rating on the shares. Competitive one-time net pricin...

Simply Wall St 5d

Analysts Have Made A Financial Statement On Intellia Therapeutics, Inc.'s First-Quarter Report

A week ago, Intellia Therapeutics, Inc. ( ) came out with a strong set of first-quarter numbers that could potentially lead to a re-rate of the stock. Revenues...

TipRanks 7d

Intellia Therapeutics Receives Buy Rating from Mitchell Kapoor Amid Promising Pipeline Developments and Accelerated Milestones

In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Intellia Therapeutics (NTLA – Research Report), with a price target...

Analyst ratings

76%

of 29 ratings

Buy

75.9%

Hold

20.7%

Sell

3.4%

People also own

Based on the portfolios of people who own NTLA. This list is generated using Robinhood data, and it’s not a recommendation.